Performance of the DETECT Algorithm for Pulmonary Hypertension Screening in a Systemic Sclerosis Cohort
- 27 July 2021
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatology
- Vol. 73 (9) , 1731-1737
Abstract
Objective: Pulmonary arterial hypertension (PAH) is one of the leading causes of mortality in systemic sclerosis (SSc). This study was undertaken to assess predictive accuracies of the DETECT algorithm and the 2015 European Society of Cardiology/European Respiratory Society (ESC/ERS) guidelines in SSc patients who underwent right‐sided heart catheterization (RHC) for pulmonary hypertension (PH) evaluation.Methods: Patients with SSc who had diagnostic RHC, had no PH or had PAH, and had available data on variables to allow application of the DETECT and 2015 ESC/ERS guidelines were included for analysis. PH classification was based on hemodynamics using the 2018 revised criteria and extent of lung fibrosis shown on high‐resolution computed tomography. Sensitivity and predictive accuracies of the DETECT algorithm and 2015 ESC/ERS guidelines were calculated, including analysis of subjects with a diffusing capacity for carbon monoxide (DLco) of ≥60% predicted.Results: Sixty‐eight patients with SSc had RHC, of whom 58 had no PH and 10 had PAH. The mean age was 60.0 years, and 58.8% had limited cutaneous SSc. The DETECT algorithm had a sensitivity of 1.00 (95% confidence interval [95% CI] 0.69–1.00) and a negative predictive value (NPV) of 1.00 (95% CI 0.80–1.00), whereas the 2015 ESC/ERS guidelines had a sensitivity of 0.80 (95% CI 0.44–0.97) and an NPV of 0.94 (95% CI 0.81–0.99). In patients with a DLco of ≥60% (n = 27), the DETECT algorithm had a sensitivity of 1.00 (95% CI 0.29–1.00) and an NPV of 1.00 (95% CI 0.59–1.00), whereas the 2015 ESC/ERS guidelines had a sensitivity of 0.67 (95% CI 0.09–0.99) and an NPV of 0.94 (95% CI 0.71–1.00).Conclusion: The DETECT algorithm has high sensitivity and NPV for diagnosis of PAH, including among individuals with a DLco of ≥60%.Keywords
Funding Information
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (K24‐AR‐063120, R01‐AR‐07047)
This publication has 15 references indexed in Scilit:
- Systemic sclerosisThe Lancet, 2017
- 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertensionEuropean Respiratory Journal, 2015
- A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosisArthritis Research & Therapy, 2015
- Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT studyAnnals of the Rheumatic Diseases, 2014
- Screening patients with scleroderma for pulmonary arterial hypertension and implications for other at-risk populationsEuropean Respiratory Review, 2013
- Recommendations for Screening and Detection of Connective Tissue Disease–Associated Pulmonary Arterial HypertensionArthritis & Rheumatism, 2013
- Survival and Predictors of Mortality in Systemic Sclerosis‐Associated Pulmonary Arterial Hypertension: Outcomes From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma RegistryArthritis Care & Research, 2013
- Screening for pulmonary arterial hypertension in patients with systemic sclerosis: Clinical characteristics at diagnosis and long‐term survivalArthritis & Rheumatism, 2011
- Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)European Heart Journal, 2009
- Diagnosis and Assessment of Pulmonary Arterial HypertensionJACC, 2009